leisure time -WSS

leisure time

author：explore 2025-09-30 01:14:55 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

WSS

Use doctors trained outside the U.S. to ease the physician shortage

UpToDate has a racism problem: Dr. Stanley Goldfarb

Childbirth

Biohaven protein

Report: NIH

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

explore

leisure time

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Childbirth

Peter Hotez and the public health issue of online harassment

Startling documents reveal new facets of Sacklers' opioid empire

United colonoscopy coverage change 'may cost lives,' doctors say

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Cancer drug shortages should be causing more outrage

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

Dobbs anniversary: the lost opportunity of abortion as health care

Report: NIH

hotspot

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Do more moles mean more problems? Not so, says new study

Prescription digital therapeutics are key to pharma’s future

What affirmative action's end means to a medical student

A letter from the executive editor: The 2023 STATUS List

AstraZeneca lung cancer study comes in below expectations

entertainment

knowledge

explore

entertainment